The Parker Institute for Cancer Immunotherapy and start-up Xyphos Biosciences are teaming up to develop universal and controllable CAR T-cell therapies that can treat many kinds of cancers. Whereas the two CAR T-cell therapies on the market are engineered to attack one particular protein, Xyphos is designing what it calls convertible CAR T cells, which can be redirected to many targets. The cells are activated by bispecific antibodies that bind a CAR T cell at one end and the cancer cell at the other end. Xyphos expects to test its first therapy in humans in early 2020.
You Might Also Like...
Researchers identify three-drug combination that helps curb the growth of deadly type of skin cancer
UCLA Jonsson Comprehensive Cancer Center | June 6, 2019
Diabetes, Cancer Organizations Launch $10 Million Research Effort
Philanthropy News Digest | May 29, 2019